CoLucid Pharmaceuticals Inc. (CLCD) Insider Linda C. Hogan Sells 2,581 Shares of Stock
CoLucid Pharmaceuticals Inc. (NASDAQ:CLCD) insider Linda C. Hogan sold 2,581 shares of the stock in a transaction on Wednesday, October 5th. The shares were sold at an average price of $37.22, for a total value of $96,064.82. Following the transaction, the insider now directly owns 719 shares in the company, valued at $26,761.18. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.
Shares of CoLucid Pharmaceuticals Inc. (NASDAQ:CLCD) traded up 1.41% during midday trading on Friday, reaching $36.77. The company’s stock had a trading volume of 32,205 shares. The firm’s market capitalization is $563.83 million. CoLucid Pharmaceuticals Inc. has a 12-month low of $3.60 and a 12-month high of $39.27. The stock has a 50-day moving average of $22.84 and a 200 day moving average of $11.23.
CoLucid Pharmaceuticals (NASDAQ:CLCD) last released its quarterly earnings results on Wednesday, August 10th. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.84) by $0.22. Equities research analysts predict that CoLucid Pharmaceuticals Inc. will post ($3.91) EPS for the current fiscal year.
A number of equities analysts recently commented on CLCD shares. Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $21.00 target price on shares of CoLucid Pharmaceuticals in a report on Thursday, September 1st. Stifel Nicolaus raised their target price on CoLucid Pharmaceuticals from $27.00 to $30.00 and gave the stock a “buy” rating in a report on Monday, September 19th. Zacks Investment Research cut CoLucid Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, September 9th. Finally, Ladenburg Thalmann raised their target price on CoLucid Pharmaceuticals from $23.00 to $52.00 and gave the stock a “buy” rating in a report on Tuesday, September 6th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $33.05.
Institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in shares of CoLucid Pharmaceuticals by 1.2% in the second quarter. Vanguard Group Inc. now owns 76,242 shares of the biopharmaceutical company’s stock worth $623,000 after buying an additional 900 shares during the period. FMR LLC bought a new stake in shares of CoLucid Pharmaceuticals during the second quarter worth $554,000. Finally, Societe Generale bought a new stake in shares of CoLucid Pharmaceuticals during the second quarter worth $464,000. 30.47% of the stock is currently owned by institutional investors and hedge funds.
About CoLucid Pharmaceuticals
CoLucid Pharmaceuticals, Inc is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies.
Receive News & Stock Ratings for CoLucid Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CoLucid Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.